The Cu(II) complex 1, Cu(II)-6-N-3,5-di-tert-butylsalicylidene-6,7-quinoxalinol-diamine, has been developed to address problems with current methods of catalytic oxidation using tert-butyl hydroperoxide (TBHP). Complex 1 demonstrated an increased capability to utilize TBHP while limiting interference from free radical reactions and was demonstrated to be highly effective in the oxidations of a variety of olefins.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: